跳至主要内容
临床试验/DRKS00013907
DRKS00013907已完成不适用

Effects of Nasal-High Flow therapy on obstructive sleep apnoea and autonomic nervous system function in patients with pulmonary-arterial hypertension

Department für Neurologie - Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster0 个研究点目标入组 12 人开始时间: 2018年8月6日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
12

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional
分配方式
N/a: Single Arm Study
盲法
Open (masking not used)

入排标准

年龄范围
18 Years 至 one(—)
性别
All

入选标准

  • a. Age > 18 years (no age limit)
  • b. able to consent
  • c. Diagnosis of Nizza class I pumonary arterial Hypertension -PAH- according to the most recent Guidelines of the European Society of Cardiology (ESC); >12 weeks since the diagnosis of PAH has been made; no hospitalisation for HF in the last 4 weeks; optimal medical therapy in accordance with the most recent Guidelines of the European Society of Cardiology (ESC) with no change in medication in the last 4 weeks and combination for PAH -where there was no treatment with combination therapy in PAH patients then the reason must be documented-
  • d. Presence of at least moderate obstructive sleep apnea
  • e. Adequate tolerance of nasal mask based cPAP treatment of OSA

排除标准

  • - secondary (postcapillary) pulmonary hypertension (mean pulmonary arterial hypertension > 25 mmHg; PCWP >15 mmHg)
  • - other severe internistic pre-existing conditions, especially insulin-dependent diabetes or severe renal impairment
  • - severe neurological pre-existing conditions such as stroke, especially brainstem infarction
  • - intake of opioids
  • - severe psychiatric pre-existing conditions

研究者

发起方
Department für Neurologie - Klinik für Schlafmedizin und neuromuskuläre Erkrankungen Universitätsklinikum Münster

相似试验

Effects of Nasal-High Flow therapy on obstructive... | 临床试验